• Genmab average return on tangible equity for 2023 was 16.88, a 7.61% increase from 2022.
• Genmab average return on tangible equity for 2022 was 18.27, a 0.44% decline from 2021.
• Genmab average return on tangible equity for 2021 was 18.35, a 40.44% decline from 2020.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.